Sector: MedicalMDVN (NASDAQ: MDVN)
Headlines
- Medivation to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
Nov 11, 2009 08:01 AM | MDVN
- Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Nov 04, 2009 04:02 PM | MDVN
- Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease
Nov 03, 2009 08:00 AM | MDVN, PFE
- Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
Oct 28, 2009 08:02 AM | MDVN
- Kyodo economic news summary
Oct 27, 2009 11:43 PM | HMC, MDVN, NSANY, TM
- Astellas, U.S. firm to develop, commercialize prostate cancer drug
Oct 27, 2009 08:49 PM | MDVN
- Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Oct 27, 2009 07:30 AM | MDVN
- Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Oct 26, 2009 05:00 PM | MDVN
- Medivation Names Hank Mansbach, M.D., Vice President of Medical Affairs
Oct 23, 2009 08:01 AM | MDVN, VRX
- Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Sep 23, 2009 08:02 AM | MDVN
- Movers: Alcoa, VMware, Office Depot, Indymac, Novartis
Jul 09, 2008 10:50 AM | AA, APOL, CAH, EMC, GBX, HELE
- Medivation Reports Second Quarter 2009 Financial Results and Provides Corporate Update
Aug 05, 2009 04:01 PM | MDVN
- Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Jul 30, 2009 08:35 AM | MDVN, PFE
- Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009
Jul 29, 2009 08:02 AM | MDVN
- Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Jun 11, 2009 08:01 AM | MDVN
- Medivation to Present at 8th Annual Needham Life Sciences Conference
Jun 04, 2009 08:01 AM | MDVN
- Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Jun 02, 2009 09:24 AM | MDVN
- Medivation Announces Pricing of Public Offering
May 27, 2009 08:53 PM | MDVN
- Medivation Selects ProTrials to Conduct International Phase III Clinical Trials
May 27, 2009 10:02 AM | MDVN
- Medivation Announces Offering of 2,750,000 Shares of Common Stock
May 26, 2009 04:55 PM | MDVN
- Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
May 21, 2009 08:02 AM | MDVN
- Form 4 MEDIVATION, INC. For: Nov 11 Filed by: Machado Clarence Patrick (10K)
Nov 13, 2009 08:13 PM
- Form 4 Bailey Gregory For: Sep 14 (10K)
Sep 15, 2009 08:18 PM
- Form 4 Machado Clarence Patrick For: Sep 09 (10K)
Sep 11, 2009 02:39 PM
- Form 4 Hung David For: Sep 09 (10K)
Sep 11, 2009 02:37 PM
- Form 4 Seely Lynn For: Sep 09 (10K)
Sep 11, 2009 02:36 PM
- Form 4 PALEKAR ROHAN For: Sep 09 (10K)
Sep 11, 2009 02:35 PM
- Form 4 Bailey Gregory For: Jul 09 (10K)
Jul 13, 2009 02:44 PM
- Form 4 PALEKAR ROHAN For: Jun 30 (10K)
Jul 02, 2009 03:09 PM
- Form 4 Machado Clarence Patrick For: Jun 30 (10K)
Jul 02, 2009 03:08 PM
- Form 4 Hung David For: Jun 30 (10K)
Jul 02, 2009 03:08 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
MDVN
|
Compare to S&P
|
| YTD |
92.38 %
|
58.91 %
|
| 4 Weeks |
2.19 %
|
1.65 %
|
| 12 Weeks |
8.60 %
|
1.91 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -44.83 %
|
|
EPS Growth in Last Year: 38.24 %
|
|
Sales Growth in Last Quarter: 0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
